Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

Clin Transl Oncol. 2020 Jan;22(1):21-36. doi: 10.1007/s12094-019-02134-7. Epub 2019 Jun 6.


Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, it has been agreed to divide stage III into sub-stages IIIA, IIIB and IIIC that have very different 5-year survival rates (36, 26 and 13%, respectively). Currently, it is considered that both staging and optimal treatment of stage III NSCLC requires the joint work of a multidisciplinary team of expert physicians within the tumour committee. To improve the care of patients with stage III NSCLC, different scientific societies involved in the diagnosis and treatment of this disease have agreed to issue a series of recommendations that can contribute to homogenise the management of this disease, and ultimately to improve patient care.

Keywords: Chemotherapy; Induction therapy; Lung cancer; Multidisciplinary team; Multimodal management; Radiotherapy; Staging; Surgery.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / pathology
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Chemoradiotherapy / mortality*
  • Consensus
  • Disease Management
  • Humans
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Lymph Node Excision / mortality*
  • Neoplasm Staging
  • Survival Rate